Clinical Trials

47 enrolled

Lung Neoplasms

NCT06467357 2026-05-14

DESTINY-BTC01

620 enrolled

Biliary Tract Neoplasms

NCT07361497 2026-05-14

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

850 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03706690 2026-05-13

PACIFIC-5

407 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT04379596 2026-05-13

DG-03

Phase 2 Recruiting

450 enrolled

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04550260 2026-05-13

KUNLUN

640 enrolled

Esophageal Squamous Cell Carcinoma

NCT02264678 2026-05-12

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

354 enrolled

Gynecologic

Ovarian Neoplasms

NCT02453282 2026-05-12

MYSTIC

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03819465 2026-05-12

MAGELLAN

175 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07081633 2026-05-12

TREMENDOUS-2

114 enrolled

Carcinoma, Hepatocellular

NCT03459846 2026-05-11

BAYOU

154 enrolled 13 charts

Genitourinary

Urinary Bladder Neoplasms

NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

286 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06667908 2026-05-11

CONVERGE

Phase 2 Recruiting

130 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05170204 2026-05-06

HORIZON 1

68 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07195695 2026-05-06

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03775486 2026-05-01

ORION

401 enrolled 26 charts

Non-small Cell Lung Cancer NSCLC

NCT04999969 2026-04-30

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

126 enrolled 30 charts

Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

NCT05883644 2026-04-30

SIERRA

111 enrolled

Liver Neoplasms

NCT06103864 2026-04-30

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

625 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05063565 2026-04-29

ROWAN

100 enrolled

Phase 3 Not yet recruiting

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT07554339 2026-04-28

KANDLELIT-015

310 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02143466 2026-04-24

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

344 enrolled

Phase 1/2 Active not recruiting

Advanced Non Small Cell Lung Cancer

NCT03742102 2026-04-24

BEGONIA

243 enrolled 13 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04745689 2026-04-24

TAZMAN

31 enrolled 15 charts

Small Cell Lung Carcinoma

NCT03833154 2026-04-23

PACIFIC-4

724 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06960577 2026-04-23

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

150 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03043872 2026-04-22

CASPIAN

987 enrolled 42 charts 1 FDA

Small Cell Lung Carcinoma

NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations